Top-News
Professionelle Dienstleistungen Kanada

Edesa Biotech Inc News

Aktie
WKN:  A3EWWS ISIN:  CA27966L3065 US-Symbol:  EDSA
3,86 €
-0,40 €
-9,39%
02.04.24 13:36:02
Handeln Depot/Watchlist
Aktienanzahl *
3,01 Mio.
Marktkapitalisierung *
12,71 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
*Stand: 13.10.2023

Edesa Biotech Inc News

30.09.22 - PR Newswire
Thinking about buying stock in F45 Training, Edesa Biotech, Amyris, Carnival Corp, or Intercept Pharmaceuticals?
Thinking about buying stock in F45 Training, Edesa Biotech, Amyris, Carnival Corp, or Intercept Pharmaceuticals? PR Newswire
08.09.22 - ACCESSWIRE
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
07.09.22 - ACCESSWIRE
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
Primary Endpoint To Be Reached Within 30 Days, With Topline Data Available by End of Year Company Evaluating Partnership and Out-​Licensing Opportunities Outside North ...
12.08.22 - ACCESSWIRE
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ...
03.08.22 - ACCESSWIRE
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
11.07.22 - ACCESSWIRE
Edesa Biotech to Present at ARDS Drug Development Summit
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
24.05.22 - ACCESSWIRE
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
19.05.22 - ACCESSWIRE
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
13.05.22 - ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
28.04.22 - ACCESSWIRE
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-​in-class, anti-​inflammatory drug TORONTO, ON / ACCESSWIRE ...
29.03.22 - ACCESSWIRE
Edesa Biotech Appoints Strategy Expert to Board of Directors
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
24.03.22 - ACCESSWIRE
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
22.03.22 - ACCESSWIRE
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-​related ...
17.02.22 - ACCESSWIRE
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
14.02.22 - ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
26.01.22 - ACCESSWIRE
Edesa Biotech to Join Ontario Bioscience Panel Discussion
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
13.01.22 - ACCESSWIRE
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, ...
28.12.21 - ACCESSWIRE
Edesa Biotech Reports Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
01.12.21 - ACCESSWIRE
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-​stage biopharmaceutical company focused on inflammatory and immune-...
04.11.21 - ACCESSWIRE
Edesa Biotech Extends COVID-19 Clinical Study to Poland
Expansion to European Union country follows favorable Phase 2 results Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 ...

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »